Genmab — November 2014
-
Ja
-
vi fik også dataene på ASCO men der var de imature for average treatment var lave (kun ca. 4 i 16 mg. armen)... Vi skulle gerne have 20 weeks treatments for næstne alle patienter nu
-
ja revlimid data + de første velcade og pomalyst data. Hamrende spændende
-
-
Slide 10: MOR202 – Preclinical Results Demonstrate Synergies with Pomalidomide
The third abstract covers additional pre-clinical studies of MOR202 in combination with the immunomodulator pomalidomide. The cytotoxic activity of MOR202 on multiple myeloma cells was enhanced and synergized when combined with pomalidomide via multiple mechanisms, namely direct cytotoxicity, CD38 up-regulation and activation of effector cells. -
These results provide a mechanistic rationale for combining MOR202 and pomalidomide. As previously communicated, we have added two additional cohorts to the ongoing MOR202 trial, where we will test MOR202 in combination with pomalidomide and with lenalidomide. These studies will start in Q1 of 2015.
-
-
Der bliver på CC også spurgt til Genmabs ASH abstract hvor de præklinisk sammenligner CD38 antistofferne - her falder MOR202 ikke specielt heldigt ud. MorphoSys mener det er for tidligt at sammenligne før der er kliniske data - og de har heller ikke lavet MOR202 som MorphoSys gør det, altså kan der måske være forskelle, siges der.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind